Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

Open access
Owen, C.N., Bai, X., Quah, T., Lo, S.N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I.L.M., Thompson, N., Vanella, V., Gerard, C.L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C.U., Welsh, S.J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J.L., Ascierto, P.A., Zimmer, L., Johnson, D.B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M.S., Sullivan, R.J., Long, G.V., Menzies, A.M. · 2021 · Annals of Oncology

Abstract

BACKGROUND IrAEs typically occur within 4 months of starting anti-PD1-based therapy (anti-PD1 +/- anti-CTLA4), but delayed irAEs (onset >12 months after commencement) can also occur. This study describes the incidence, nature and management of delayed irAE in patients receiving anti-PD1-based immunotherapy. METHODS Patients with delayed irAEs from 20 centres were studied. The incidence of delayed irAEs was estimated as a proportion of melanoma patients treated with anti-PD1-based therapy and surviving >1 year. Onset, clinical features, management and outcomes of irAEs were examined. RESULTS 118 patients developed a total of 140 delayed irAEs (20 after initial combination with anti-CTLA4); with an estimated incidence of 5.3% (95% CI 4.0-6.9, 53/999 patients at sites with available data). The median onset of delayed irAE was 16 months (range 12-53). 87 patients (74%) were on anti-PD1 at irAE onset, 15 patients (12%) were <3 months from last dose, 16 patients (14%) were >3 months from last dose of anti-PD1. The most common delayed irAEs were colitis, rash and pneumonitis; 55 of all irAEs (39%) were ≥G3. Steroids were required in 80 patients (68%), as well as an additional immunosuppressive agent in 27 patients (23%). There were two irAE-related deaths: encephalitis with onset during anti-PD1, and a multiple organ-irAE with onset 11 months after ceasing anti-PD1. Early irAEs (<12 months) had also occurred in 69 patients (58%), affecting a different organ from the delayed irAE in 59 patients (86%). CONCLUSIONS Delayed irAEs occur in a small but relevant subset of patients. Delayed irAEs are often different from previous irAE, may be high grade and can lead to death. They mostly occur in patients still receiving anti-PD1. The risk of delayed irAE should be considered when deciding duration of treatment in responding patients. However, patients who stop treatment may also rarely develop delayed irAE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2021.03.204

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 172

Metadata

Authors
Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C. U., Welsh, S. J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J. L., Ascierto, P. A., Zimmer, L., Johnson, D. B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M. S., Sullivan, R. J., Long, G. V., & Menzies, A. M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-07
Volume
32
Issue
7
Pages
917-925
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3148902978
Cited by
172
References
8
FWCI
10.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. https://app.cochat.ai/papers/10.1016/j.annonc.2021.03.204
The paper
Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., . . . Menzies, A. M. (2021). Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.03.204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.